wet AMD

The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals for a supplemental biologics licence application (sBLA) for EYLEA (aflibercept) injection in patients with wet age-related macular degeneration (AMD). Read more


A brief round up of some of the latest developments in the industry, including a review into medical marijuana and a potential win for Trump in drug pricing… Read more


Genentech has unveiled positive results from its Phase II LADDER study, which evaluated the efficacy and safety of its investigational Port Delivery System with ranibizumab (PDS) in people with wet age-related macular degeneration (AMD). Read more


According to data and analytics company, GlobalData, pharmaceutical sales within the age-related macular degeneration (AMD) markets will soar to $11.5 billion by the year 2026. Read more


The controversy surrounding Avastin and Lucentis has reared its head again as it has been revealed that health chiefs may face a legal fight if they go ahead with plans to offer the cheaper drug (Avastin) to patients with wet AMD on the NHS Read more